Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Editorial: Cellular Therapies in Cancer.
Rafei H, Mehta RS, Rezvani K. Rafei H, et al. Front Immunol. 2019 Nov 27;10:2788. doi: 10.3389/fimmu.2019.02788. eCollection 2019. Front Immunol. 2019. PMID: 31827476 Free PMC article. No abstract available.
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. Li Y, et al. Among authors: rafei h. Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29. Nat Med. 2022. PMID: 36175679 Free PMC article.
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K. Li L, et al. Among authors: rafei h. Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26. Sci Adv. 2023. PMID: 37494448 Free PMC article.
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Olson A, et al. Among authors: rafei h. J Clin Oncol. 2021 Aug 20;39(24):2710-2719. doi: 10.1200/JCO.20.02608. Epub 2021 Apr 30. J Clin Oncol. 2021. PMID: 33929874 Free PMC article. Clinical Trial.
Targeting advanced urothelial carcinoma-developing strategies.
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Alhalabi O, et al. Among authors: rafei h. Curr Opin Oncol. 2019 May;31(3):207-215. doi: 10.1097/CCO.0000000000000532. Curr Opin Oncol. 2019. PMID: 30844889 Review.
Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Ravindranathan D, et al. Among authors: rafei h. Adv Exp Med Biol. 2021;1342:143-192. doi: 10.1007/978-3-030-79308-1_5. Adv Exp Med Biol. 2021. PMID: 34972965 Review.
41 results